Multiplexed Mass Spectrometry Solutions for Cancer Proteomics
Tuesday, December 12th, 2017
8 am PT, 11 am ET, 1700 CET
Translational proteomics workflows place much greater emphasis on biological replicate analysis of large, well-defined cohorts instead of fewer samples and greater numbers of technical replicates. These also need to be quantitative, with changes across cohorts of samples measured to be precise and accurate. Multiplexed tandem mass tag (TMT) solutions offer greater parallelization potential in quantitative mass spectrometry experiments resulting in greater throughput.
In this Clinical OMICs webinar, the use of TMT based multiplexing quantitative proteomics for profiling subcutaneously implanted breast cancer patient-derived xenografts (PDXs) will be discussed. PDXs are the best model of primary human tumors and enable cancer researchers to study drug response and tumor biology. The stroma plays an important role in breast cancer progression. In PDX models, the tumor-associated stroma is mouse-derived and can be differentiated from the tumor (human-derived) by analysis of species-unique peptides. Precise and accurate TMT-based multiplexed quantitative proteomics enabled us to discover, in a cohort of 21 breast PDX tumors, that the education of the stroma was highly individualized but biologically coordinated. In particular, proteins involved in immune signaling varied in a subtype- and stage-specific manner. These findings may have future implications for treatment stratification and provide a platform from which to understand tumor-stroma interactions on a large-scale protein level.
You Will Learn
- Development of multiplexed quantitative, standardized, reproducible, and precise proteomic workflows
- The use of isobaric tags such as tandem mass tags (TMT) for translational proteomics
- Quantitative proteomics analysis of breast cancer patient-derived xenografts (PDXs) using species-unique peptides
For Research Use Only. Not for use in diagnostic procedures.